The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up
- Steinberg, Martin H.
- McCarthy, William F.
- Castro, Oswaldo
- Ballas, Samir K.
- Armstrong, F. Danny
- Smith, Wally
- Ataga, Kenneth
- Swerdlow, Paul
- Kutlar, Abdullah
- DeCastro, Laura
- Waclawiw, Myron A.
- Orringer, E.
- Jones, S.
- Strayhorn, D.
- Rosse, W.
- Phillips, G.
- Peace, D.
- Johnson-Telfair, A.
- Daitch, L.
- Milner, P.
- Tracy, A.
- Valdez, S.
- Allen, G. E.
- Moshang, J.
- Scott, B.
- Bigelow, C.
- Anderson, A.
- Sabahi, V.
- Harrington, T.
- Labrousse, W.
- Pegelow, C.
- Temple, D.
- Case, E.
- Harrell, R.
- Childerie, S.
- Embury, S.
- Schmidt, B.
- Davies, D.
- Saunthararajah, Y.
- Koshy, M.
- Talischy-Zahed, N.
- Dorn, L.
- Pendarvis, G.
- McGee, M.
- Telfer, M.
- Davis, A.
- Onyekwere, O. C.
- Nwokolo, C.
- Finke, H.
- Perlin, E.
- Siteman, J.
- Bryan, M.
- Saunders, T.
- Barber, Y.
- Gascon, P.
- Di Paolo, P.
- Gargiulo, S.
- Eckman, J.
- Carter-Randall, E.
- Bailey, J. H.
- Platt, A.
- Waller, L.
- Ramirez, G.
- Knors, V.
- Hernandez, S.
- Rodriguez, E. M.
- Wilkes, E.
- Vichinsky, E.
- Hagar, W.
- Hoehner, C.
- Hackney-Stevens, E.
- Claster, S.
- Earles, A.
- Kleman, K.
- McLaughlin, K.
- White, L.
- Maddox, B.
- Usry, L.
- Brenner, A.
- Williams, K.
- O'Brien, R.
- Genther, K.
- Shurin, S.
- Berman, B.
- Chiarucci, K.
- Keverline, L.
- Olivieri, N.
- Chow, J.
- Hui, M.
- Shaw, D.
- Lewis, N.
- Okam, M.
- Mandell, E.
- Palmer, A.
- Bridges, K.
- Tynan, B.
- Winograd, C.
- Bellevue, R.
- Dosik, H.
- Sheikhai, M.
- Ryans, P.
- Souffrant, H.
- Adler, B.
- Johnson-Telfair, A.
- Eskridge, L.
- Prchal, J.
- Braddock, J.
- McArdle, T.
- Carlos, T.
- Roundtree-Schmotzer, A.
- Gardner, D.
DOIAbstract
A randomized, controlled clinical trial established the efficacy and safety of short-term use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long-term hydroxyurea usage, patients in this trial were followed for 17.5 years during which they could start or stop hydroxyurea. The purpose of this follow-up was to search for adverse outcomes and estimate mortality. For each outcome and for mortality, exact 95% confidence intervals were calculated, or tests were conducted at α = 0.05 level (p-value <0.05 for statistical significance). Although the death rate in the overall study cohort was high (43.1%; 4.4 per 100 person-years), mortality was reduced in individuals with long-term exposure to hydroxyurea. Survival ...
Add to ORKG